The NeuroAiD II (MLC901) in Vascular Cognitive Impairment Study (NEURITES)

Chen, Christopher; Ikram, Kamran; Qiu, Anqi; Yin, Wong Tien; Chen, Shen-Hsing Annabel; Venketasubramanian, Narayanaswamy

doi:10.1159/000346234

Cited by 18 publications

(12 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All these clinical results are encouraging to pursue further exploration of NeuroAid as a new efficient therapeutic strategy against stroke. Two clinical trials with MLC901 are also ongoing for assessment in vascular cognitive impairment patients [23] and in New Zealand patients with traumatic brain injury (https://www.anzctr.org.au/Trial/ Registration/TrialReview.aspx?id=364449).…”

Section: Introductionmentioning

confidence: 99%

MLC901 Favors Angiogenesis and Associated Recovery after Ischemic Stroke in Mice

Gandin

Widmann²,

Lazdunski³

et al. 2016

Cerebrovasc Dis

View full text Add to dashboard Cite

Background: There is increasing evidence that angiogenesis, through new blood vessel formation, results in improved collateral circulation and may impact the long-term recovery of patients. In this study, we first investigated the preventive action of a 5-week pretreatment of MLC901, an herbal extract preparation derived from Chinese medicine, against the deleterious effects of ischemic stroke and its effects on angiogenesis in a model of focal ischemia in mice. Methods: The stroke model was induced by 60 min of middle cerebral artery occlusion followed by reperfusion. MLC901 was administered in the drinking water of animals (6 g/l) for 5 weeks before ischemia and then during reperfusion. Results: MLC901 treatment increased the survival rate, reduced the cerebral infarct area and attenuated the blood brain barrier leakage as well as the neurologic dysfunction following ischemia and reperfusion. We provide evidence that MLC901 enhances endothelial cell proliferation and angiogenesis by increasing the number of neocortical vessels in the infarcted area. MLC901 regulates the expression of hypoxic inducible factor 1α and its downstream targets such as vascular endothelial growth factor and angiopoietins 1 and 2. This work also shows that erythropoietin is an important player in the enhancement of angiogenesis by MLC901. Conclusions: These results demonstrate therapeutic properties of MLC901, in addition to those previously described, in stimulating revascularization, neuroprotection and repair of the neurovascular unit after ischemic stroke.

show abstract

Section: Introductionmentioning

confidence: 99%

MLC901 Favors Angiogenesis and Associated Recovery after Ischemic Stroke in Mice

Gandin

Widmann²,

Lazdunski³

et al. 2016

Cerebrovasc Dis

View full text Add to dashboard Cite

show abstract

“…it is estimated that dementia affects around 5-8% of those aged 65 years and older, and 30% of people older than 80 (1,5,11). vaD is the second most common cause of cognitive impairment in the elderly after AD, constituting 15-20% of all dementia worldwide (12,13). The incidence of vaD increases with age, without any significant difference between men and women (1).…”

Section: Epidemiology and Risk Factorsmentioning

confidence: 99%

“…The incidence of vaD increases with age, without any significant difference between men and women (1). The Canadian Study of Health and Ageing prospective cohort study of 10,253 elderly persons reported that patients with vCi had a higher rate of institutionalization and death, while half of those who had vCiND developed dementia within 5 years (13,14,15). it is also important to emphasize that stroke prevalence is 6 times higher in those with cognitive impairment relative to normal (16).…”

Section: Epidemiology and Risk Factorsmentioning

confidence: 99%

Vascular Cognitive Impairment

Jianu¹,

Timisoara²,

Bârsan³

2019

Ro J Neurol.

View full text Add to dashboard Cite

Vascular cognitive impairment (VCI) is a heterogeneous group of cognitive disorders that share a presumed vascular cause and it is the second most common cause of cognitive impairment in the elderly after Alzheimer's disease. Its prevalence is estimated to double over the next 30 years. Vascular cognitive impairment encompasses cases related to multiple cortico-subcortical infarcts, silent infarcts, strategic infarcts, small vessel disease, as well as mixed pathology. It is important to emphasize that some of the risk factors for vascular dementia are the same as for stroke, including high blood pressure, diabetes, heart disease and cigarette smoking. Compared with Alzheimer's disease, vascular dementia has a higher rate of mortality and a slower rate of cognitive decline. The aim of the treatment in vascular cognitive impairment is mainly to identify and reduce the effect of the vascular risk factors. This article aims to resume the most important data regarding VCI.

show abstract

“…In addition, there are several ongoing studies on the use of NeuroAiD in poststroke cognitive impairment and TBI [17-19]. …”

Section: Introductionmentioning

confidence: 99%

Spinal Cord Injury—Assessing Tolerability and Use of Combined Rehabilitation and NeuroAiD (SATURN Study): Protocol of An Exploratory Study In Assessing the Safety and Efficacy of NeuroAiD Amongst People Who Sustain Severe Spinal Cord Injury

Kumar¹,

Htwe²,

Baharudin³

et al. 2016

JMIR Res Protoc

View full text Add to dashboard Cite

BackgroundSpinal cord injury (SCI) is a devastating condition with limited therapeutic options despite decades of research. Current treatment options include use of steroids, surgery, and rehabilitation. Nevertheless, many patients with SCI remain disabled. MLC601 (NeuroAiD), a combination of natural products, has been shown to be safe and to aid neurological recovery after brain injuries and may have a potential role in improving recovery after SCI.ObjectiveThe aim of this study is to evaluate the safety and efficacy of NeuroAiD amongst people who sustain SCI in the study setting.MethodsSpinal Cord Injury—Assessing Tolerability and Use of Combined Rehabilitation and NeuroAiD (SATURN) is a prospective cohort study of patients with moderately severe to severe SCI, defined as American Spinal Injury Association (ASIA) Impairment Scale (AIS) A and B. These patients will be treated with open-label NeuroAiD for 6 months in addition to standard care and followed for 24 months. Anonymized data will be prospectively collected at baseline and months 1, 3, 6, 12, 18, and 24 and will include information on demographics; main diagnostics; and neurological and functional state assessed by the Spinal Cord Independence Measure, ASIA—International Standard for Neurological Classification Spinal Cord Injury, and Short Form (SF-8) Health Survey. In addition, NeuroAiD treatment, compliance, concomitant therapies, and side effects, if any, will be collected. Investigators will use a secured online system for data entry. The study is approved by the ethics committee of Hospital University Kebangsaan Malaysia.ResultsThe coprimary endpoints are safety, AIS grade, and improvement in ASIA motor score at 6 months. Secondary endpoints are AIS grade, ASIA motor scores and sensory scores, Spinal Cord Independence Measure (SCIM), SF-8 Health Survey, and compliance at other time points.ConclusionsSATURN investigates the promising role of NeuroAiD in SCI especially given its excellent safety profile. We described here the protocol and online data collection tool we will use for this prospective cohort study. The selection of moderately severe to severe SCI provides an opportunity to investigate the role of NeuroAiD in addition to standard rehabilitation in patients with poor prognosis. The results will provide important information on the feasibility of conducting larger controlled trials to improve long-term outcome of patients with SCI.Trial RegistrationClinicaltrials.gov NCT02537899; https://clinicaltrials.gov/ct2/show/NCT02537899 (Archived by WebCite at http://www.webcitation.org/6m2pncVTG)

show abstract

The NeuroAiD II (MLC901) in Vascular Cognitive Impairment Study (NEURITES)

Cited by 18 publications

References 44 publications

MLC901 Favors Angiogenesis and Associated Recovery after Ischemic Stroke in Mice

MLC901 Favors Angiogenesis and Associated Recovery after Ischemic Stroke in Mice

Vascular Cognitive Impairment

Spinal Cord Injury—Assessing Tolerability and Use of Combined Rehabilitation and NeuroAiD (SATURN Study): Protocol of An Exploratory Study In Assessing the Safety and Efficacy of NeuroAiD Amongst People Who Sustain Severe Spinal Cord Injury

Contact Info

Product

Resources

About